Investigation of CYP3A4*22 polymorphism effects on the depressed treatment by citalopram and sertraline

Abstract

Abstract Drug response variability due to interpersonal genetic differences is a new and vital research interest. Many single nucleotide polymorphisms (SNPs) have been characterized for CYP3A4 (alleles *1–*22). PCR-RFLP method performed to check CYP3A4*22 polymorphism as an important allele in drug metabolism. 45 Blood samples were collected from the Iranian population with the depressive disorder. Hamilton Depression Rating Scale (HAM-D) used for evaluate the severity of depression before and after 100 days of treatment. Among the individuals, 40 (91.2%) patients showed wild type (CC) and 5 (91.2%) patients were heterozygous (CT) for the CYP3A4*22 allele. Comparing the rate of decrease in HAM-D score between two genotypic groups in CYP3A4*22 showed a significant difference (p < 0.03). This comparison demonstrated that patients with heterozygote genotype of CYP3A4*22 have improved by SSRIs lower than wild-type of patients. It can be concluded that CYP3A4*22 genotype and dose adjustment can help improve drug treatment.